Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways -NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc.
This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.
CANANDAIGUA — Representatives of Ronald McDonald House, Rochester and The Maddie B. Childhood Cancer Foundation joined UR ...
A father is appealing for donors as his teenage son faces a life-threatening blood disorder and needs a stem cell transplant within weeks to improve his chances of survival.
A big blue bus will soon be traveling across Texas, and it’s the first of its kind for making cutting-edge medical technology more accessible.
Thejangulie Mekro seen celebrating after winning the men's basketball championship title in the recently concluded Nagaland Olympic and Paralympic Games 2022, a ...
For the full year 2025, Sellas Life Sciences contained its net loss to $26.86 million. A particularly strong fourth quarter saw the company post a loss per share of $0.05, a result that surpassed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results